Author Topic: (Abst.) Management of infusion-related reactions associated w/Lemtrada...  (Read 13 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 7908
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, October 24, 2017:

Quote
Mult Scler Relat Disord. 2017 Oct;17:151-153.

Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis

ega-Jazbec S1, Barun B2, Horvat Ledinek A1, Fabekovac V2, Krbot Skorić M2, Habek M3.

Author information

1
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
2
Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia.
3
Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address: mhabek@mef.hr.

OBJECTIVE:

Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) treated with alemtuzumab. We aimed to study the frequency of IARs at 2 sites using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols.

METHODS:

This was retrospective chart review of 38 consecutive MS patients who were treated with alemtuzumab from June 2015 till February 2017 at Department of Neurology, University Hospital Center Zagreb, Croatia and Department of Neurology, University Medical Center Ljubljana, Slovenia.

RESULTS:

Seventeen patients (44.7%) did not experience IARs. Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions and they were most frequent on Day 5 and Day 1, respectively. We have observed significant differences in the occurrence of fever (p = 0.005) depending on the site of alemtuzumab administration which could be explained by different antipyretics used; fever was absent in the Slovenian cohort because high dose intravenous metamizole was administered. Two out of 9 treatment nave, and 19 out of 29 patients who previously received immunomodulatory treatment had IARs (χ2 = 5.208, p = 0.022).

CONCLUSION:

Modified premedication scheme consisting of 1g/day of IV methylprednisolone throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous administration of antipyretics may work better than oral administration.

The abstract can be seen here.
MS Speaks--online for 12 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
45 Views
Last post April 01, 2016, 08:57:14 am
by agate
0 Replies
39 Views
Last post May 22, 2016, 12:13:55 pm
by agate
0 Replies
17 Views
Last post January 21, 2018, 03:41:12 pm
by agate
0 Replies
21 Views
Last post January 25, 2018, 04:31:23 pm
by agate
0 Replies
12 Views
Last post July 23, 2018, 07:49:08 pm
by agate